{"nct_id":"NCT05809895","title":"Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer","status":"WITHDRAWN","status_verified_date":"2023-07","start_date":"2023-09-15","start_date_type":"ESTIMATED","primary_completion_date":"2029-07-17","primary_completion_date_type":"ESTIMATED","completion_date":"2029-07-18","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["NVS"]}